Oligo-PROTAC strategy for cell-selective and targeted degradation of activated STAT3
Jeremy Hall,Zhuoran Zhang,Supriyo Bhattacharya,Dongfang Wang,Marice Alcantara,Yong Liang,Piotr Swiderski,Stephen Forman,Larry Kwak,Nagarajan Vaidehi,Marcin Kortylewski
DOI: https://doi.org/10.1016/j.omtn.2024.102137
IF: 10.183
2024-02-07
Molecular Therapy — Nucleic Acids
Abstract:Decoy-oligodeoxynucleotides (ODN) allow for targeting undruggable transcription factors, such as STAT3, but their limited potency and lack of delivery methods hampered translation. To overcome these challenges, we conjugated STAT3-specific decoy to thalidomide, a ligand to cereblon in E3 ubiquitin ligase complex, to generate a proteolysis-targeting chimera (STAT3D PROTAC ). STAT3D PROTAC downregulated STAT3 in target cells, but not STAT1 or STAT5. Computational modeling of the STAT3D PROTAC ternary complex predicted two surface lysines K601 and K626 in STAT3 as potential ubiquitination sites. Accordingly, K601/K626 point mutations in STAT3, as well as proteasome inhibition or cereblon deletion alleviated STAT3D PROTAC effect. Next, we conjugated STAT3D PROTAC to a CpG oligonucleotide targeting Toll-like receptor 9 (TLR9) to generate myeloid/B-cell-selective C-STAT3D PROTAC . Naked C-STAT3D PROTAC was spontaneously internalized by TLR9+ myeloid cells, B-cells, human and mouse lymphoma cells but not by T cells. C-STAT3D PROTAC effectively decreased STAT3 protein levels and also STAT3-regulated target genes critical for lymphoma cell proliferation and/or survival ( BCL2L1, CCND2, MYC ). Finally, local C-STAT3D PROTAC administration to human Ly3 lymphoma-bearing mice triggered tumor regression while control C-STAT3D and C-SCR treatments had limited effects. Our results underscore feasibility of using PROTAC strategy for cell-selective, decoy oligonucleotide-based STAT3 targeting of and potentially other tumorigenic transcription factors for cancer therapy.
medicine, research & experimental